Trials / Completed
CompletedNCT01303991
Hexvix Photodynamic Therapy in Patients With Bladder Cancer
A Phase I Feasibility Study of Hexvix Photodynamic Therapy in Patients With Intermediate or High-risk Bladder Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Photocure · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate the safety and feasibility of Hexaminolevulinate based photodynamic therapy in patients with intermediate or high-risk transitional cell carcinoma of the bladder.
Detailed description
Non-muscle invasive bladder cancer is currently treated by transurethral resection (TURB) and/or fulguration. However, recurrence and progression rates following endoscopic treatment of visible lesions are significant. To prevent recurrent and progressive disease, adjuvant intravesical chemotherapy and immunotherapy are applied. There is also increasing interest in new therapeutic strategies such as photodynamic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Hexvix PDT with Karl Storz T-Light |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2011-02-25
- Last updated
- 2011-02-25
Source: ClinicalTrials.gov record NCT01303991. Inclusion in this directory is not an endorsement.